Jellagen launches JellaGel™
The first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix.
READ POSTThe first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix.
READ POSTJellagen announces the appointments of Dr Mike Barbeck and Dr Andy Weymann to the Scientific Advisory Board
READ POSTJellagen were visited by the BBC who wanted to talk to us about our jellyfish collagen and the opportunities it creates
READ POSTThe companies will act as exclusive distributors of Jellagen’s products and services across their respective regions of India and South Korea.
READ POSTjellagen has entered into a license agreement for an exclusive grant to patent rights with Mayo Clinic for the development in treatment of vocal cord paralysis.
READ POSTMicroglia Cells on Jellagen® demonstrated a more ramified “microglial-like” cell morphology compared to cells cultured on mammalian Rat Tail Collagen I and Laminin-511
READ POSTIn Vivo Analysis of the Biocompatibility and Immune Response of Jellyfish Collagen Scaffolds and its Suitability for Bone Regeneration
READ POSTThe £1.9m round, which was 75% funded by international investors, will enable Jellagen to develop and partner pipeline products aimed at tissue reconstruction, diabetic wound care management and rare skin diseases.
READ POSTJellagen was shown to have an increased level of synchronisation when compared against Matrigel
READ POSTDiscover why collagen is such an important component for successful cell culture
READ POST